Drug Trial Radar · NCT03100825
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
Last checked: Nov 19, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Apr 28, 2017
Primary completion
Sep 18, 2018
Study completion Apr 8, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.
Conditions
- Asthma
Interventions
QVM149Drug
QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs)Time frame: Up to 52 Weeks
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Koga, Fukuoka, Japan
Novartis Investigative Site
Yanagawa, Fukuoka, Japan
Novartis Investigative Site
Maebashi, Gunma, Japan
Novartis Investigative Site
Hiroshima, Hiroshima, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Tomakomai, Hokkaido, Japan
Novartis Investigative Site
Takamatsu, Kagawa-ken, Japan
Novartis Investigative Site
Fujisawa, Kanagawa, Japan
Novartis Investigative Site
Sagamihara, Kanagawa, Japan
Novartis Investigative Site
Sagamihara, Kanagawa, Japan
Novartis Investigative Site
Yokohama, Kanagawa, Japan
Novartis Investigative Site
Yokkaichi, Mie-ken, Japan
Novartis Investigative Site
Nagaoka, Niigata, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Sakai, Osaka, Japan
Novartis Investigative Site
Ageo, Saitama, Japan
Novartis Investigative Site
Chuo Ku, Tokyo, Japan
Novartis Investigative Site
Chuo-ku, Tokyo, Japan
Novartis Investigative Site
Chuo-ku, Tokyo, Japan
Novartis Investigative Site
Chuo-ku, Tokyo, Japan
Novartis Investigative Site
Ōta-ku, Tokyo, Japan
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan
Novartis Investigative Site
Setagaya-ku, Tokyo, Japan
Novartis Investigative Site
Shinagawa-ku, Tokyo, Japan
Novartis Investigative Site
Toshima Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.